Hopp til innhold

Get alerts of updates about «Vaccination for Human Papillomavirus (HPV) (Indicator 22)»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Vaccination for Human Papillomavirus (HPV) (Indicator 22)

Vaccination for Human Papillomavirus (HPV) (Indicator 22)

The indicator describes the following: Vaccination coverage for human papilloma virus (HPV) vaccine.

The indicator describes the following: Vaccination coverage for human papilloma virus (HPV) vaccine.

A vaccine against human papillomavirus (HPV) is included in the Norwegian Childhood Immunisation Programme and is given at 12 years (7th grade). The vaccine has been offered to girls since 2009 and to boys since 2018. In addition there was a limited catch-up programme from 1 November 2016 to 30 June 2019 for young women born in 1991 or later. In this programme, women who had never been offered or had previously declined the offer in the Childhood Immunisation Programme were offered the vaccine for free.  The Norwegian Immunisation Registry (SYSVAK) provides statistics of the vaccination coverage for HPV vaccination. 


The official vaccination coverage for the HPV vaccine is given for 16-year-olds. The vaccination coverage among 16-year-old girls who are fully vaccinated increased from 67 per cent to 92 per cent between 2013 and 2021 (see figure 1). The official vaccination coverage for fully-vaccinated boys will not be available until 2023. The proportions of vaccinated boys and girls are monitored continuously and for the 2007 cohort, 94 per cent of girls and 93 per cent of  boys have received at least one dose of HPV vaccine (as of August 2021). 59 per cent of young women born between 1991 and 1996 have received at least one dose of HPV vaccine during the time-limited catch-up programme. 

HPV vaksine EN 2022.PNG
Figure 1. Vaccination coverage for fully-vaccinated girls aged 16, as a percentage. Source: Norwegian Immunisation Registry SYSVAK  .


Table accompanying Figure 1
2013 2014 2015 2016 2017 2018 2019 2020 2021
67 76 79 81 88 88 89 89 92


Data source: Norwegian Immunisation Registry (SYSVAK)

The data source for this indicator is the Norwegian Immunisation Registry (SYSVAK). A description follows below.


The Norwegian Immunisation Registry (SYSVAK) maintains an overview of the individual's vaccination status and vaccination coverage in Norway. 

The Norwegian Childhood Immunisation Programme includes a range of different vaccines recommended by the health authorities for children and adolescents. 

The Norwegian Institute of Public Health is responsible for procuring the vaccines for the Norwegian Childhood Immunisation Programme and distributing them to the municipalities. Vaccination takes place at well-baby clinics and through the school health service and is free of charge. All administered vaccines are registered at individual level in SYSVAK.

The Norwegian Childhood Immunisation Programme publishes an annual report that includes vaccination coverage, reported cases of diseases for which vaccination is provided through the programme, and the type of vaccines that have been used.

Effect measure

  • Vaccination coverage for girls aged 16 years who are fully vaccinated with the HPV vaccine, as a percentage. 

The figures apply to those who are fully vaccinated, i.e. they have received the recommended number of doses with the recommended intervals between doses. In the Childhood Immunisation Programme, the HPV vaccine was administered in a three-dose schedule from autumn 2009 until autumn 2017. Since autumn 2017, the vaccine has been administered in a two-dose schedule.

The HPV vaccine is offered at 12 years (7th grade).  The official vaccination coverage is calculated for 16-year-olds. The first cohort of boys to have been offered the vaccine through the Childhood Immunisation Programme are born in 2006. Therefore they are not currently included in the official statistics of vaccination coverage.  

National adaptation to global indicator definition

WHO’s definition of the indicator

Indicator 22. Availability, as appropriate, if cost-effective and affordable, of vaccines against human papillomavirus, according to national programmes and policies. 

National adaptation

The WHO indicator applies to vaccine availability. The Norwegian indicator includes vaccination coverage.


05.10.2022: Updated with 2021 figures

Authors and contacts

Text compiled by the Section for Vaccine Epidemiology and Population Studies at the Department of Methods Development and Analytics, and the Department of Chronic Diseases at the Norwegian Institute of Public Health.